Using a murine transplantation model, we have investigated the function of the HPV16 E6 and E7 proteins in the development of radiation resistance in advanced cervical carcinoma. Constitutive high-level expression of the HPV16 E6 oncogene in HPV negative human C33A cervical carcinoma cells was shown to induce rapid onset and radiation resistance in transplanted tumors when compared with tumors derived from E7 or vector transfected cells. The radiationresistant, E6 tumor phenotype was not due solely to increased hypoxia, because all E6 tumors were shown to be uniformly hypoxic, and artificial induction of hypoxia, in E7 and control tumors, failed to produce the same degree of radiobiological resistance. Differential screening of a 1.2-k human cancer cDNA array indicated that E6 tumors had up-regulated expression of the DNA nucleotide excision repair gene excision repair cross-complementation enzyme 1 (ERCC1). High-level expression of ERCC1 mRNA and protein was found to be restricted to radiation-resistant E6 tumors. In vitro maintenance of E6 and control vector-expressing cells under anoxic conditions showed that ERCC1 expression was induced preferentially in E6-expressing cells. These data indicate that the HPV16 E6 protein may influence the response to therapy of cervical carcinoma by inappropriate activation of DNA repair mechanisms.
It has been established that high-risk human papilloma virus (HPV's) 16, 18 , and others are involved in the etiology of at least 90% of cervical carcinomas (5) . Previous work (6) (7) (8) has shown that the HPV-encoded oncoproteins E6 and E7 are retained and expressed in cervical tumors and cell lines after viral replication has ceased. Both of these cDNAs are expressed as a single bicistronic message (5) , and in vitro studies have shown that continued expression of both E6 and E7 proteins are required for maintenance of the transformed phenotype (9, 10) . Indeed, both of these oncoproteins are expressed in most cases of advanced metastatic disease, and it has been observed that high levels of E6 mRNA in peripheral blood are coincident with disease dissemination and poor prognosis (11) .
The HPV16 E6 protein is known to act in concert with cellular proteins to produce the degradation of p53 (12) , which has prompted investigation into the effects of E6 on radiation resistance. Previous work has indicated that expression of HPV16 E6 in vitro does not affect the radio-resistance of tumor cells expressing either mutant, null, or wild-type p53 (13) (14) (15) but can increase the resistance of normal fibroblasts to radiation (16) . Studies in vivo have suggested that expression of E6 and E7 can alter the radiation-induced, DNA damage response of normal skin fibroblasts (17) . We have investigated the effect of independent constitutive expression of HPV16 E6 and E7 oncoproteins on the in vivo growth characteristics and radio-resistance of transplanted tumors derived from the papilloma virus-negative, human cervical carcinoma cell line C33A. These cells have a p53 codon 273 Arg-Cys mutation (18) , thus any observed effects should be independent of some of the known functions of wild-type p53.
METHODS

Production of E6 and E7 expressing cell lines
HPV-negative human C33A cervical carcinoma cells (a kind gift of P. L. Stern, Paterson Institute for Cancer Research, Manchester, UK ) were grown at 37 o C, 5% CO 2 in RPMI (GIBCO, Paisley, England), 5% fetal calf serum (Sigma Aldrich Chemical Co., Poole, Dorset, UK). The HPV16 E6 (477 bp) and E7 (297 bp) cDNAs (HPV 16 genomic DNA obtained from S. Stacey, Paterson Institute of Cancer Research) were cloned into pcDNA 3.1 (Invitrogen, 9704 CH Groningen, The Netherlands), which was linearized and transfected into C33A cells by lipofection (Lipofectamine, GIBCO). Vector-only transfected control C33A cells were also produced. Analysis of G418 (0.5 mg/ml, resistant colony formation indicated that similar transfection efficiencies were obtained for E6, E7, and vector only (data not shown). Transfected polyclonal cell populations were selected by growth in the presence of G418 for 3 weeks. Singlecell/colony clonal cell lines were derived from the original E6, E7, and control transfected polyclonal C33A populations by a combination of single-cell fluorescent activated cell sorter (FACS) sorting and single-colony picking.
Growth of cells under reduced oxygen conditions
Cell lines were maintained at 37 o C, 5% CO 2 under anoxic conditions for 24 h by the use of a controlled oxygen incubator (Laboratory Thermal Equipment, UK).
RNA extraction and Northern blotting
We performed RNA extraction by using the acid phenol method (19) , and we analyzed cell lines for expression of E6 and E7 by using Northern blotting (20). Hybridization and washing conditions used were as described previously (21). We performed imaging with a direct imager (Packard Instruments, Pangbourne, Berks UK).
P-labeled probes
These probes were produced by the use of a random prime labeling kit according to the manufacturer's instructions (Boehringer Mannhein, Roche Diagnostics Ltd, Lewes, E. Sussex, England).
Western immunoblotting
We performed this task on proteins isolated from cell lines and tumors as described previously (21), by using 1:200 dilutions of anti p53 monoclonal antibody Pab240, anti Hif-1α polyclonal antibody C19 (Santa Cruz, Wembley, UK) anti-ERCC1 monoclonal Ab-1 (NeoMarkers, Freemont, CA), and anti-actin A2066 (Sigma Immunochemicals, Gillingham, Dorset, UK). Horseradish peroxidase conjugated secondary antibodies (DAKO, Ely, Cambridgeshire, UK) were applied at dilutions of 1:2000.
In vivo transplantation of E6 and E7 transfected cells
All investigations conformed to the Animals (Scientific Procedures) Act U.K. 1986. The principles of laboratory animal care were followed. Male and female mice of the inbred SCID strain (Harlan Olac, Bicester, UK) were subcutaneously implanted with 5 × 10 5 cells from control, E6, and E7 expressing polyclonal or monoclonal cell lines. Tumors were established, from which samples were taken for RNA extraction, the remainder were macerated and mixed, and the same number of cells was reinjected. This procedure was repeated for each subsequent in vivo passage. However in these first studies, no more than four passages were used before being returned to the source material.
Tumor growth measurement
Tumors were measured daily with vernier callipers across three orthogonal diameters: length (L), width (W), and thickness (T) from which volumes (V) were approximated by the formula V = (L × W × T)/2. Animals were killed when tumor volumes reached 800-1000 mm 3 .
X-irradiation of tumors
Animals were treated in groups of five per tumor type and per X-ray dose plus a control (shamirradiated) group. Tumors were treated at a volume of 125 mm 3 . The body was shielded by lead such that only the tumor was exposed to X-rays from a PANTAK instrument (300 KV, 10 mA; Pantak Ltd., Reading, UK). In certain groups, radiobiological hypoxia was induced by clamping the blood supply of the tumor for 30 min before and during irradiation (controls in this instance were clamped but not irradiated). We measured postirradiation changes in tumor volume, and we calculated the time was required to reach eight times treatment volume. This value was divided by the mean value for the relevant control, to yield a relative growth delay. The mean growth delays of each dose group for E6 and E7 tumors were then compared with vector-only control, for single radiation doses between 10 and 50 Gy. This was initially carried out separately on male and female animals, but we found no significant differences between the two sexes, therefore these data have been pooled. We repeated the dose groups and pooled the data a minimum of two times.
Statistical analysis
We used the Two-Tailed t-test analysis of statistical significance.
cDNA array screening
Tumors were excised, and RNA was extracted (19) and prepared for 32 P-labeled cDNA probe synthesis according to the Clontech Atlas cDNA array screening manual (Clontech Labs, UK, Basingstoke, Hampshire, UK). Human cancer 1.2 cDNA arrays (Clontech) were probed and washed according to the manufacturer's instructions. We used a phosphorimager (Molecular Dynamics, Amersham/Pharmacia, Buckinghamshire, England) to perform imaging.
PCR of ERCC1 cDNA probe
This was carried out on 10 ng of oligo T-primed E6 tumour cDNA using the primers TTGAGGCTCCAAGACCAG and TTTCCTTGGCAGCTGGG for 25 cycles of 94 o C, 30sec; 51 o C, 30 sec; 72 o C, 1 min. The product was 980 bp in length.
RESULTS
E6 and E7 transfected cell lines
Comparison of the growth rates of high E6, low E6, and vector-only monoclonal cell lines showed no difference (data not shown). However, we did observe that high E6-expressing cells were more motile and tended to grow in suspension in large clumps, which agrees with previous work (22) . Furthermore, when plated at low density, E6 cells went through a noticeable lag until growth in clumps was established, whereupon the growth rate accelerated to equal that of vector control cells. No other morphological differences were noted. Figure 1 shows the Northern analysis of the expression of E6 and E7 transcripts in transfected C33A cells. a) Illustrates the various levels of E6 expression obtained in E6 transfected, polyclonal and monoclonal cell lines. b) Shows the E7 signal obtained with polyclonal transfected C33A cells. It proved difficult to isolate long-term, stably transfected E7 monoclonal cell lines. Although some monoclonal E7 cell lines were isolated, the level of E7 RNA in these cultures was generally below that of detection for Northern blot. The transcript was, however, readily detectable by PCR in both tumors and cells (data not shown). Figure 1c shows the results of a Western immunoblot of proteins isolated from the E6-Mono high and the Vector-Mono cell lines (Fig. 1a) probed with an anti-p53 monoclonal antibody. Because the E6 transfected cells have no detectable p53 signal, it is clear that the Arg-Cys codon 273 mutant form of p53 present in C33A cell is susceptible to degradation stimulated by the E6 protein. Furthermore, this finding also confirms that the E6 protein is being produced in an active form in these cells.
Expression of E6 and E7 in cell lines
Analysis of p53 protein levels in E6 transfected cells
Comparison of tumor growth rates
Figure 2a demonstrates the in vivo growth characteristics of tumors that were derived from subcutaneous injection of SCID mice with E6-Poly, E7-Poly, and Vector-Poly cells. Animals inoculated with E6 cells developed tumors approximately 10 days earlier than those inoculated with E7 cells, which in turn were 5-7 days earlier than animals inoculated with vector only cells. These results were highly reproducible, and each of the data points shown represents the means of 15 animals. We found no significant difference in tumor growth between male and female animals. Once established, the in vivo growth rates were similar for all three tumor types. Animals injected with the E6-Mono High cells (Fig. 1a ) also displayed the characteristic early presentation of E6 tumors derived from polyclonal tranfectants (data not shown). Figure 2b illustrates the mean relative tumor growth delay that was obtained for each tumor type after graded single doses of radiation were given with the tumor not clamped. E6 expressing tumors were resistant to radiation when compared with vector and E7 expressing tumors (P<0.05). The artificial induction of hypoxia, by clamping the tumor blood supply, produced an increase in the radiation resistance of E7 tumors at doses up to 20 Gy (P<0.001) (Fig. 2c) . By contrast in E6 tumors, we found no difference in the response at any dose between 10 and 50 Gy. At 30 Gy for E7 and vector-only tumors, we found no significant difference between nonclamped and clamped tumors, which is consistent at least with the nonclamped tumors regrowing from a largely hypoxic population. However, hypoxia alone was insufficient to produce the same degree of radiobiological resistance seen in E6 tumors (Fig. 2c) . Within the E6 arm, some variation in radiation response was seen between individual tumors, which is exemplified by the results shown later on in Figure 3a for second-passage tumors that were derived by inoculation with pooled polyclonal material.
Effect of X-irradiation on tumor growth
cDNA array screening Table 1 shows the results of differential screening of a 1.2 human cancer cDNA array with cDNA probes made from RNA isolated from third-passage, nonirradiated tumors derived from E6-Poly and Vector Poly cells. This list represents only those cDNAs that were markedly either up-or down-regulated. VEGF-B (vascular endothelial growth factor B) was also up-regulated in E6 tumors but not to the same extent. Figure 3a shows the in vivo growth of second in vivo passage E6-Poly-derived tumors treated with an X-ray dose of 20 Gy. It can be seen that three of these tumors (animals 1, 2, and 3) showed very little response, whereas two (animals 4 and 5) showed a partial response to treatment. RNA was extracted from these tumors and was analyzed by Northern blot (Fig. 3b) . The expression levels of excision repair cross-complementation enzyme 1 (ERCC1) and E6 in these second-passage 20Gy treated E6-tumors indicated that high-level expression of both E6 and ERCC1 was restricted to E6 tumors with the radiation-resistant phenotype (animals 1, 2, and 3). E6 tumors that showed a partial response to treatment had lower levels of both E6 and ERCC1 (animals 4 and 5). No control or E7 tumors showed any up-regulated ERCC1 expression. Furthermore, analysis of the levels of ERCC1 in E6 transfected cells grown in vitro did not show any up-regulated ERCC1 expression irrespective of the level of E6 (first 7 lanes, Fig. 3b ). Southern blot comparison of the ERCC1 genomic copy number showed no difference between control, E6, or E7 tumors (data not shown).
Analysis of ERCC1 expression in cells in vitro and in second passage radiation treated tumors
Analysis of ERCC1 protein levels in 20Gy treated E6 tumors
Western immuno-blot analysis (Fig. 3c ) demonstrated that ERCC1 protein expression was also up-regulated in the radiation-resistant E6 tumors (animals 1, 2, and 3) when compared with ERCC1 protein levels in the two E6 tumors with greater radiosensitivity (animals 4 and 5). Figure 3c clearly demonstrates that expression of the E6 protein was maintained in tumors because the levels of p53 protein were predictably low in all high E6-expressing tumors tested (animals 1, 2, and 3).
Analysis of p53 expression in E6 tumors
Analysis of hypoxic inducible factor (Hif-1α) expression in E6 tumors
We can see, as shown in Figure 3c , that the E6 tumors all express Hif-1α and that there was no significant difference in levels of this protein between the radiation-resistant and radiationresponsive E6 tumors.
Analysis of ERCC1 expression in primary tumors
RNAs isolated from primary in vivo passage tumors were analyzed for expression levels of ERCC1 by Northern blot (Fig. 4a) . Two out of three primary E6 tumors had up-regulated expression of ERCC1 (Fig. 5a , lanes 5 and 6), whereas vector-only and E7 tumors had not.
ERCC1 expression in cell lines under aerobic anoxic growth conditions
Although the E6-Poly and E6-Mono High cells had high-level expression of E6, these cells did not have up-regulated ERCC1 expression in vitro, when grown under standard oxygen partial pressures (see previous Fig. 3b ). The E6-Mono High cell line and the Vector-Mono cell line were then maintained under anoxic conditions for 24 h. Analysis of RNA extracted from these cultures by Northern blot (Fig. 4b) showed that growth in the absence of oxygen markedly induced ERCC1 expression in the E6-Mono High cell line. Although some increase also occurred in the Vector-Mono cell line, this increase was much less marked than that observed with E6 transfectants.
DISCUSSION
Our data demonstrate that high-level expression of the HPV16 E6 oncoprotein in tumors derived from transplanted human C33A cervical carcinoma cells confers an aggressive radiation-resistant phenotype. This condition was not observed with E7-expressing or control-vector-only tumors. Some human solid tumors are considerably less well oxygenated than normal tissues, and it is well established that this condition can lead to resistance to radiotherapy and anticancer chemotherapy, as well as predisposition to increased tumor metastases. However, the radiationresistant E6 tumor phenotype cannot be explained solely by levels of radiobiological hypoxia. Artificial induction of tumor hypoxia, before and during radiation treatment, increased the resistance of E7 tumors at lower radiation doses, as expected, although still not to the same extent as that observed for E6 tumors irradiated "in air". The detection of the Hif-1α protein in E6 tumors confirmed their hypoxic status. Furthermore, since we did not find different levels of Hif-1α protein in radiation-resistant and radiation-sensitive E6-tumors, this indicates that other factors, in addition to hypoxia, must be involved in the radiation resistant E6 tumor phenotype.
Changes in gene expression associated with E6 tumors included elevated mRNA expression of several factors known to be involved in angiogenesis; for example, PDGF, NF kappa, VEGF-B, FGF receptor 1, and the proinflammatory cytokine interferon gamma. This finding may provide an explanation for the earlier onset of macroscopic disease with E6 tumors, presumably by increased stimulation of neovascularization, which in turn facilitates more rapid growth in the initial stages of development. This result cannot be explained by differences in the in vitro cloning efficiency between parent cell lines because comparison of these indicated that E6 cells had the lowest colony-forming ability (data not shown). Predictably, analysis of the levels of p53 protein in these tumors indicated that lower levels of E6 expression were coincident with higher levels of p53 (Fig. 3c) .
The ERCC1 also showed marked mRNA up-regulation in two out of three primary in vivo passage E6 tumors. This condition was not seen in any primary passage control or E7 tumors. As subsequent in vivo passages were carried out with pooled primary tumors, we would expect that the E6 innoculum would contain clones expressing both low and high levels of ERCC1. Was high-level expression of ERCC1 consistent with increased E6 tumor radiation resistance? Northern blots of in vitro polyclonal/monoclonal cells, and second-passage polyclonal tumors probed with ERCC1, indicated that high-level expression was indeed restricted to X-ray resistant E6 tumors; whereas the two E6 tumors that showed low-level expression of ERCC1 demonstrated a partial response to X-ray treatment (Fig. 3b) . Furthermore, reprobing this blot with E6 showed a clear correlation between the levels of E6 and ERCC1 expression. Western immunoblots confirmed that the ERCC1 protein was also elevated in high E6-expressing, radiation-resistant tumors. It is probable that the two E6 tumors with increased radio-sensitivity were derived from cells that originated from the single, low ERCC1-expressing, primary tumor (Fig. 4a, lane 4) . This finding would suggest that tumors derived from high E6-expressing clones have a radiation-resistant, survival advantage attributable, at least in part, to enhanced DNA repair capabilities. In support of this finding, we have also inoculated animals with E6-Mono High C33A cells, and it is clear that high-level expression of E6 promotes the more rapid tumor development and radiation resistance that is associated with high ERCC1 expression (data not shown).
A recent in vitro study (23) has also indicated that ERCC1 RNA levels may be a molecular marker of cisplatin resistance in cultured cervical carcinoma cells, although the authors concluded that the level of ERCC1 protein did not always correlate with this observation. Our in vivo data demonstrate that higher ERCC1 protein levels are associated with radiation resistance in E6 tumors (Fig. 3c) .
What is the mechanism responsible for the up-regulation of ERCC1 expression? We have shown that the codon 273 Arg-Cys mutant p53 in C33A cells is degraded by E6, and it has been previously demonstrated that mutant p53 can still function to stabilize the genome and prevent the development of hyperploidy (24) . Because it is known that expression of the HPV16 E6 protein can produce genetic instability (25), we analyzed the genomic copy number of ERCC1 in E6 tumors and cell lines. Southern blot analysis (data not shown) demonstrated no amplification of the ERCC1 gene in high E6-expressing tumors, which indicates that the observed upregulation must be caused by either increased transcriptional activation or increased half-life of the ERCC1 transcript.
Numerous DNA repair proteins play a role in the radiation-resistance of tumors (26, 27) . In this regard, we have also analyzed the mRNA expression levels, in E6 and vector-only tumors, of several genes contained on the 1.2-k cancer array known to be involved in the DNA repair process. DNA-PK, Ku70, XRCC4, and ATM were expressed in both tumor types and did not show any significant change in expression levels. Rad51C truncated protein showed decreased expression in the E6 tumor, whereas Rad51 was up-regulated. This condition was not, however, as pronounced as that observed for ERCC1.
ERCC1 is part of an endonuclease complex involved in both nucleotide excision repair (NER) of bulky chemical adducts and recombination repair (RR) of highly genotoxic interstrand DNA cross-links (28, 29) . A role for ERCC1 in X-ray sensitivity is consistent with previous findings that have demonstrated that the ERCC1/ERCC4 complex catalyzed RR-dependent pathway for the removal of DNA interstrand cross links is associated with radiation resistance under hypoxic conditions (30, 31) . Furthermore, it has been shown that antisense inhibition of ERCC1 expression suppresses the synergism observed between the cytotoxic drug cisplatin and the radiation-sensitizing drug gemcitabine (32, 33) . Therefore, these data are supportive of a role for ERCC1 in the resistance of E6-expressing tumors to X-ray treatment.
We did not find any evidence of increased ERCC1 expression in high E6-expressing cells when grown under aerobic conditions in vitro. Indeed, a recent study failed to demonstrate a consistent correlation between the expression levels of several DNA repair genes and radiation sensitivity in vitro (34) . The overall conclusion from this work was that the in vitro environment may not accurately reproduce the in vivo requirements necessary for induction of DNA repair enzymes involved in tumor radiation resistance. Because the work of Murray et al (30, 31) has shown that ERCC1 is clearly involved in the radiobiological resistance of cells under hypoxic conditions, we investigated the effect of hypoxia on the induction of ERCC1 expression in vitro. Growth of high E6-expressing C33A cells under anoxic conditions in vitro produced a modest but more pronounced induction of ERCC1 than in vector-only control cells. Clearly, the tumor environment is an important factor in the induction of genes involved in radiation resistance, and our data are consistent with this hypothesis.
We propose the following scheme, based on our experimental observations, for the development of radiation resistance in relapsed cervical carcinoma following radiotherapy (<5% 5-y survival (4)). It has been shown that low-dose X-irradiation induces higher levels of E6 expression in cultured cervical carcinoma cells (3), presumably by induction of a p53-mediated killing response in cells expressing lower levels of E6. Thus, cells that survive the first round of radiotherapy may have increased expression of E6. Intracellular levels of E6 mRNA can vary according to the HPV integration status. The HPV early protein E2 functions as a negative regulator of E6/E7 transcription; thus disruption of the HPV E2 open reading frame, which is a common feature of HPV integration (35) , could produce increased expression of E6. Indeed, it has been observed that detection of integrated HPV in primary tumors of cervical carcinoma patients was strongly associated with treatment failure (36) . Our results indicate that high-level expression of E6 will facilitate high-level expression of ERCC1 under hypoxic tumor conditions. Because ERCC1 has been shown to be involved in the repair of both radiation damage by RR and alkylating agent damage by NER, our data may also provide an explanation of the phenomenon of radiation-induced chemoresistance in cervical carcinomas (3). We are currently investigating this hypothesis by analyzing tumor biopsies from cervical carcinoma patients who relapse and from those who are well following radiotherapy. 
